| Drug General Information |
| Drug ID |
D0H4AD
|
| Former ID |
DNC010118
|
| Drug Name |
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C13H18BrNO
|
| Canonical SMILES |
CC(C(=O)C1=CC=C(C=C1)Br)NC(C)(C)C
|
| InChI |
1S/C13H18BrNO/c1-9(15-13(2,3)4)12(16)10-5-7-11(14)8-6-10/h5-9,15H,1-4H3
|
| InChIKey |
QYLKSFXBRALDIS-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
|---|
| Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
| Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Alcoholismhsa04726:Serotonergic synapse
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
|
Parkinson disease
|
|
Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
|
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
|
Reactome
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
|
|
WikiPathways
|
Monoamine Transport
|
|
NRF2 pathway
|
|
Dopaminergic Neurogenesis
|
|
Parkinsons Disease Pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
|
Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport
|
|
SIDS Susceptibility Pathways
|
|
Synaptic Vesicle Pathway
|
|
Serotonin Transporter ActivityWP727:Monoamine Transport
|
| References |
| REF 1 | J Med Chem. 2010 Mar 11;53(5):2204-14.Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. |
|---|
